AstraZeneca Coronavirus Vaccine Clinical Trial Paused
According to an article in Stat, AstraZeneca (NYSE: AZN) has paused the U.S. clinical trial of its coronavirus vaccine, AZD1222, after a serious possible adverse event arose in a patient enrolled in a clinical trial testing AZD122 in the U.K.
At this point, the nature of the adverse event is not known, and it isn't clear whether it was caused by AZD122. The company is "working to expedite the review of the single event to minimize any potential impact on the trial timeline," according to Stat. The participant is expected to recover.
In addition to the 30,000-participant U.S. study announced last week, AstraZeneca is also running clinical trials in the U.K., Brazil, and South Africa. The company plans to start studies in Japan and Russia as well. All told, the studies will enroll up to 50,000 participants globally.
Source Fool.com